New Report On Acomplia's Potential Sales
Written by Stuart Stevens | Tuesday, 20 March 2007 | There are 0 comments
The clinical gold standard for treating obesity...
A new report that concerns the weight loss drug Acomplia has recently been released and it notes that it is likely to replace Xenical as the world’s best selling diet medicine. The report took into account the fact that Acomplia is still not available for sale in America due to the problem that the Food and Drug Administration have not given it the green light yet but nevertheless they believe that by the year 2010, Acomplia will overtake Xenical in terms of sales and become as they called it “ the clinical gold standard for treating obesity”.
The report that was written by a company called Decision Resources involved a lot of research about different methods of treating overweight and obese people as well as interviews with over 3,000 endocrinologists. The report also took into account the fact that a number of other companies are soon likely to ask for FDA approval for their weight loss drugs that could be serious competition for Acomplia.
Acomplia or Zimulti as it will be known in America when it finally gets FDA approval works as an appetite suppressant. In clinical trials it is seen to be very effective but the reason it is being stopped at the FDA has nothing to do with the drug's effectiveness but more to do with the problem that there have been some incidents of people getting depressed when using the medicine. The UK was the first European country to license Acomplia for sale and it is selling well in the UK. About eight other European countries now have Acomplia on the shelves of their pharmacies.
A number of other weight loss drugs that we’re likely to hear about in the near future are Lorcaserin [APD356] made by Arena Pharmaceuticals and also Cetilistat [ATL-962] made by Alizyme. The drug company Merck [which is famous for making the hair loss drug Propecia], as well as Pfizer [which is famous for making the erectile dysfunction drug Viagra], are both making and presently testing in clinical trials their own weight loss drugs and these could also be serious competition for the Acomplia diet drug.
